Active substance
Results for the substance atezolizumab
3 results
About this active substance
Atezolizumab is an immunotherapy drug used in the treatment of certain types of cancer. It is a monoclonal antibody that works by blocking the PD-L1 protein (programmed death-ligand 1), allowing the immune system to recognize and destroy cancer cells.
It is indicated for the treatment of non-small cell lung cancer (NSCLC), urothelial (bladder) cancer, triple-negative breast cancer, and other advanced or metastatic cancers. Atezolizumab is administered intravenously, typically in a hospital or clinic setting under medical supervision.
Side effects may include fatigue, nausea, diarrhea, skin rashes, joint pain, and, in rare cases, severe autoimmune reactions that can affect organs such as the lungs, liver, or endocrine glands.
Close monitoring is essential during treatment, and the drug should be administered as directed by an oncologist.
It is indicated for the treatment of non-small cell lung cancer (NSCLC), urothelial (bladder) cancer, triple-negative breast cancer, and other advanced or metastatic cancers. Atezolizumab is administered intravenously, typically in a hospital or clinic setting under medical supervision.
Side effects may include fatigue, nausea, diarrhea, skin rashes, joint pain, and, in rare cases, severe autoimmune reactions that can affect organs such as the lungs, liver, or endocrine glands.
Close monitoring is essential during treatment, and the drug should be administered as directed by an oncologist.
-
-
TECENTRIQ 1200mg/20ml concentrate for solution for infusion EGIS ORIGINAL MEDICINE
-
TECENTRIQ 840mg/14ml concentrate for solution for infusion EGIS ORIGINAL MEDICINE